GlassScriptPhysician profile
Asim Ahmad
NPI 1447544838
$129,658.46
in general payments reported to CMS, 2019-2025
68 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $10K · 2021: $11K · 2022: $10K · 2023: $20K · 2024: $27K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Consulting Fee: $22K · Travel and Lodging: $8,539 · Food and Beverage: $8,478 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,091.00 |
| Consulting Fee | $21,691.25 |
| Travel and Lodging | $8,538.55 |
| Food and Beverage | $8,477.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $265.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31,511.25 | 2019-2025 | Reblozyl, Opdivo |
| Glaxosmithkline, LLC. | $25,833.62 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Incyte Corporation | $12,468.52 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Karyopharm Therapeutics INC. | $9,604.01 | 2020-2025 | Xpovio |
| Celgene Corporation | $7,594.36 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $6,723.96 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Kite Pharma, INC. | $4,891.00 | 2020-2025 | Yescarta |
| Sun Pharmaceutical Industries INC. | $4,496.63 | 2025 | |
| Daiichi Sankyo INC. | $3,633.29 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Pharmacosmos Therapeutics INC. | $3,433.96 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $3,023.90 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $2,737.87 | 2019-2025 | |
| Beigene USA, INC. | $2,519.26 | 2020-2024 | Brukinsa |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Janssen Biotech, INC. | $1,589.42 | 2019-2025 | Carvykti, Tecvayli |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,398.45 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $494.19 | 2020-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $476.05 | 2019-2025 | |
| Abbvie INC. | $446.29 | 2019-2025 | Venclexta |
| Puma Biotechnology, INC. | $381.87 | 2019-2021 | |
| Astellas Pharma US INC | $372.22 | 2019-2025 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $303.44 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $294.58 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Adaptive Biotechnologies Corporation | $259.49 | 2022-2025 | Clonoseq |
| Seagen INC. | $207.87 | 2019-2023 | Tukysa |
| Gilead Sciences, INC. | $192.28 | 2019-2025 | Trodelvy |
| Genmab U.S., INC. | $189.38 | 2023-2025 | Epkinly |
| Genzyme Corporation | $174.74 | 2022-2025 | |
| Adc Therapeutics America, INC. | $174.48 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $171.58 | 2020-2025 | Ultomiris |
| Amgen INC. | $161.27 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Talvey |
| Sirtex Medical INC | $146.56 | 2025 | Sir-Spheres Microspheres |
| Takeda Pharmaceuticals U.S.A., INC. | $145.53 | 2019-2025 | Fruzaqla, Vonvendi, Advate |
| Pharmaessentia USA Corporation | $135.39 | 2024-2025 | Besremi |
| Verastem, INC. | $134.31 | 2020 | |
| Eisai INC. | $127.32 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $96.14 | 2024-2025 | |
| Epizyme, INC. | $90.62 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $90.00 | 2021 | |
| Kyowa Kirin, INC. | $86.57 | 2019-2025 | |
| Morphosys, US INC. | $86.31 | 2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $76.54 | 2019-2022 | |
| Stemline Therapeutics INC. | $73.11 | 2024 | Orserdu, Elzonris |
| Sobi, INC | $65.29 | 2023-2025 | |
| Taiho Oncology, INC. | $60.34 | 2019-2024 | |
| Beone Medicines USA, INC. | $54.87 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $52.60 | 2023-2024 | Pyrukynd |
| Geron Corporation | $48.13 | 2025 | Rytelo |
| Tempus Ai, INC | $45.67 | 2024-2025 | Xt Cdx |
| Blueprint Medicines Corporation | $36.10 | 2020-2025 | Ayvakit |
| Tg Therapeutics, INC. | $35.49 | 2021-2022 | |
| Emd Serono, INC. | $31.73 | 2019 | |
| Genentech USA, INC. | $29.00 | 2019 | |
| Tersera Therapeutics LLC | $24.22 | 2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $24.05 | 2024 | Onivyde |
| Recordati_rare_diseases_inc. | $23.28 | 2025 | Sylvant |
| Alnylam Pharmaceuticals INC. | $22.83 | 2025 | Givlaari |
| Apellis Pharmaceuticals, INC. | $22.72 | 2024 | Empaveli |
| Immunocore Limited | $20.99 | 2025 | Kimmtrak |
| Syndax Pharmaceuticals, INC. | $20.93 | 2025 | |
| Acrotech Biopharma INC. | $20.10 | 2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.87 | 2019 | |
| Menarini Silicon Biosystems, INC. | $17.46 | 2023 | Cellsearch |
| Array Biopharma INC | $15.70 | 2025 | Braftovi, Tukysa, Mektovi |
| Aurobindo Pharma USA, INC. | $15.26 | 2019 | |
| Caris Mpi, INC. | $15.22 | 2025 | Mi Cancer Seek |
| Amneal Pharmaceuticals LLC | $13.98 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.